IBM’s 25% Rout: A Technical Bounce Masks the Real Question About Those Delayed Deals
Published on 07/25/2026 at 13:24 | Redaktion boerse-global.de
The worst single-day loss in IBM’s history—a 25 percent plunge on July 14, 2026—left shareholders reeling. Eleven days later, the stock clawed back 3.74 percent to close at €188.38 on Friday, a modest gain that has done little to erase the memory of a month that wiped 18.63 percent from the share price. Since the start of the year, the damage stands at 27.52 percent.
That Friday bounce, while welcome, looks more like a mechanical reflex than a genuine vote of confidence. The relative strength index (RSI) of 35.5 suggests the stock is hovering near oversold territory, a level that historically triggers short-covering and technical stabilization. But the broader picture remains firmly bearish: the shares trade nearly 20 percent below both their 50-day moving average of €228.64 and their 200-day average of €233.84, a classic configuration that signals sustained downward pressure.
What Caused the July 14 Meltdown
The trigger was a preliminary second-quarter report that missed analyst expectations on nearly every front. IBM posted adjusted earnings of $2.93 per share, falling short of the $3.01 consensus, while revenue of $17.2 billion came in well below the $17.86 billion forecast. The full quarterly release later confirmed the scale of the miss: infrastructure revenue slumped 7 percent to $3.84 billion, driven by a catastrophic 42 percent collapse in z-Mainframe sales.
CEO Arvind Krishna attributed the shortfall to a sudden shift in corporate spending patterns. Clients are diverting budgets away from traditional consulting projects and capital-intensive software deals toward generative AI hardware—specifically memory chips and related infrastructure. Krishna described the demand as “deferred, not destroyed,” noting that several software contracts in the low double-digit millions had simply been pushed back as companies scrambled to reallocate funds.
Should investors sell immediately? Or is it worth buying IBM?
IBM responded by trimming its 2026 revenue growth forecast from “over 5 percent” to a range of 4 to 5 percent. For a company that had been positioning itself as a steady-growth technology stalwart, the revision was a jarring admission that the AI boom is cannibalizing its core business rather than feeding it.
The Bull Case: Recurring Revenue and a Quantum Horizon
Supporters of the stock point to the underlying resilience of IBM’s software division, which grew 5 percent to $7.76 billion in the second quarter. Crucially, 80 percent of software revenue is now recurring, providing a buffer against quarterly volatility. The infrastructure segment also showed pockets of strength: distributed systems posted a record 37 percent growth, suggesting IBM remains relevant in modern data-center projects.
The most compelling near-term data point is that roughly one-third of the deferred software contracts were reportedly re-signed during the first three weeks of July. If that trend continues, it would validate Krishna’s “deferred, not destroyed” narrative and could trigger a meaningful recovery. The average analyst price target of €231.11 implies upside of about 22.7 percent from Friday’s close—a gap that value-oriented investors find tempting.
On the horizon sits IBM’s long-term bet on quantum computing. The company plans to invest $10 billion over five years, targeting a fault-tolerant system called “Starling” by 2029. The recent agreement to acquire HRL Laboratories, which specializes in silicon spin-qubit technology, is expected to close by the end of the third quarter. These moves are part of a broader strategy to position IBM as a leader in next-generation computing, though they generate no near-term cash flow.
The Bear Case: Structural Cannibalization
The opposing view holds that the “deferrals” are actually a permanent shift in IT spending patterns—one IBM is ill-equipped to handle. Consulting revenue grew just 1 percent last quarter, raising doubts about management’s ability to navigate the transition. The fear is that the AI arms race will continue to consume the very budgets that feed IBM’s high-margin software and services businesses.
Similar capital pressures are already visible among competitors. Alphabet, for instance, recently reported negative free cash flow as it ramps up AI infrastructure spending. For IBM, the challenge is compounded by the operational complexity of integrating HRL Laboratories alongside the earlier acquisition of HashiCorp—all during a period of weakening growth.
If the deferred deals do not fully return by the end of the third quarter, the revised 4 to 5 percent growth target could prove overly optimistic. In that scenario, a retest of the 52-week low of €175.14—just 7.56 percent below Friday’s close—becomes a real possibility.
IBM at a turning point? This analysis reveals what investors need to know now.
The Credibility Test Ahead
IBM’s management pushed back against concerns that customers are abandoning the mainframe. CFO Kavanaugh stated flatly that the company sees “no signs of clients moving off the mainframe” and expects “significant strength in this program in the second half.” Yet the market’s faith in IBM’s forecasting ability has clearly eroded. Analyst reactions to the July shock were unusually divided: Argus slashed its price target while other firms held steady, reflecting a rare level of uncertainty about the near-term outlook.
Two milestones will determine the direction. The first is the closing of the HRL acquisition, expected by the end of September. The second—and far more important—is the third-quarter earnings report, which will reveal whether the “deferred” demand is genuinely returning or whether it has been permanently lost to AI hardware budgets.
With 30-day annualized volatility hovering near 85 percent, sharp swings are likely to continue. The oversold RSI reading of 35.5 provides a technical foundation for a counter-trend rally, but the stock remains firmly in bear territory. For now, Friday’s gain looks like a relief bounce in an oversold stock—not a confirmed turnaround. The real test lies in whether those delayed deals come home.
Ad
IBM Stock: New Analysis - 25 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
